

Supplementary Table 1: Glycolytic metabolites measured at the end of aerobic perfusions

| | h-INS | h-INS/DIPR | h-INS/IL | ff-INS | ff-INS/DIPR | ff-INS/IL |
|--|----------|------------|-------------------------|------------|-------------|------------|
| glucose 6-phosphate [nmol/g dry wt] | 223 (39) | 234 (29) | 233 (29) | 214 (26) | 203 (38) | 218 (12) |
| p(ANOVA)=0.839 | | | p(ANOVA)=0.636 | | | |
| fructose 6-phosphate [nmol/g dry wt] | 55 (12) | 59 (12) | 54 (9) | 53 (44;67) | 54 (46;63) | 57 (53;73) |
| p(ANOVA)=0.720 | | | p(Kruskal-Wallis)=0.503 | | | |
| fructose-1,6-bisphosphate [nmol/g dry wt] | 25 (9) | 32 (13) | 27 (5) | 29 (9) | 17 (5)# | 27 (7) |
| p(ANOVA)=0.419 | | | p(ANOVA)=0.022 | | | |

Data are presented as mean (SD) or median (25th; 75th percentile). N=6. Analysis of variance (ANOVA) was performed to compare INS, INS/DIPR, and INS/IL from healthy (h) and from fructose-fed (ff) rats: It was followed by a multiple comparison procedure (Holm-Sidak method). If the condition of normality was not met (i.e. Shapiro-Wick test $p < 0.05$) a Kruskal-Wallis One Way Analysis of Variance on Ranks was performed.

#, significantly different from ff-INS and ff-INS/IL group.

Abbreviations are as follows: h, healthy (hearts from control rats); ff, hearts from fructose-fed rats: INS, treatment with insulin alone; INS/DIPR, treatment with insulin and Diprivan[®] (10 μ M); INS/IL, treatment with insulin and Intralipid[®].